MedWatch

Analyst emphasizes 2021 guidance in Genmab fiscal report

On Tuesday, Danish biotech firm Genmab presents its annual report, and according to bank analyst Søren Løntoft Hansen, special attention will be given to the current year's guidance.

Photo: PR / Genmab

Genmab's 2021 guidance is an unknown variable for when biotech companies start presenting fiscal reports on Tuesday after the stock market closes.

Analysts have garnered a pretty good idea of Q4 already, since Genmab's partner Johnson & Johnson published sales figures for the biotech company's major source of income Darzalex in January, already.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs